Cameroon vs Vanuatu: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Cameroon
1.8%
in 2024
Vanuatu
1.8%
in 2024
Cameroon rank
14th
Vanuatu rank
14th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Cameroon
- Vanuatu
How they compare
Cameroon currently reports 1.8% against 1.8% in Vanuatu, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Cameroon ahead.
Cameroon ranks 14th and Vanuatu ranks 14th of 215 countries.
Cameroon has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cameroon | Vanuatu | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2.0% | 1.6% | 0.4% | Cameroon |
| 2020s | 2.0% | 1.7% | 0.3% | Cameroon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Cameroon or Vanuatu?
- Cameroon, at 1.8% against 1.8% in Vanuatu as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Cameroon and Vanuatu?
- 0.0%, with Cameroon ahead.
- How many years of comparable data are there for Cameroon and Vanuatu?
- 10 years are reported by both, from 2015 to 2024.
- How do Cameroon and Vanuatu rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Cameroon ranks 14th and Vanuatu ranks 14th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.